These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21890496)

  • 1. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.
    Anderl S; Freeland M; Kwiatkowski DJ; Goto J
    Hum Mol Genet; 2011 Dec; 20(23):4597-604. PubMed ID: 21890496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
    Meikle L; Pollizzi K; Egnor A; Kramvis I; Lane H; Sahin M; Kwiatkowski DJ
    J Neurosci; 2008 May; 28(21):5422-32. PubMed ID: 18495876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.
    Carson RP; Van Nielen DL; Winzenburger PA; Ess KC
    Neurobiol Dis; 2012 Jan; 45(1):369-80. PubMed ID: 21907282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.
    Way SW; Rozas NS; Wu HC; McKenna J; Reith RM; Hashmi SS; Dash PK; Gambello MJ
    Hum Mol Genet; 2012 Jul; 21(14):3226-36. PubMed ID: 22532572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.
    Goto J; Talos DM; Klein P; Qin W; Chekaluk YI; Anderl S; Malinowska IA; Di Nardo A; Bronson RT; Chan JA; Vinters HV; Kernie SG; Jensen FE; Sahin M; Kwiatkowski DJ
    Proc Natl Acad Sci U S A; 2011 Nov; 108(45):E1070-9. PubMed ID: 22025691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
    Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
    Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.
    Way SW; McKenna J; Mietzsch U; Reith RM; Wu HC; Gambello MJ
    Hum Mol Genet; 2009 Apr; 18(7):1252-65. PubMed ID: 19150975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
    Zeng LH; Xu L; Gutmann DH; Wong M
    Ann Neurol; 2008 Apr; 63(4):444-53. PubMed ID: 18389497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
    Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
    Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models.
    Magri L; Cominelli M; Cambiaghi M; Cursi M; Leocani L; Minicucci F; Poliani PL; Galli R
    Dis Model Mech; 2013 Sep; 6(5):1185-97. PubMed ID: 23744272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
    Guo Y; Kwiatkowski DJ
    Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
    Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
    Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
    Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
    Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
    Zhang B; McDaniel SS; Rensing NR; Wong M
    PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brain proteomic investigation of rapamycin effects in the
    Wesseling H; Elgersma Y; Bahn S
    Mol Autism; 2017; 8():41. PubMed ID: 28775826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation.
    Prabowo AS; Anink JJ; Lammens M; Nellist M; van den Ouweland AM; Adle-Biassette H; Sarnat HB; Flores-Sarnat L; Crino PB; Aronica E
    Brain Pathol; 2013 Jan; 23(1):45-59. PubMed ID: 22805177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.